These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 32847555)

  • 1. New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report.
    Yamada H; Okajima F; Onda T; Fujimori S; Emoto N; Sugihara H
    BMC Endocr Disord; 2020 Aug; 20(1):132. PubMed ID: 32847555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic testing for Graves' or non-Graves' hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography.
    Scappaticcio L; Trimboli P; Keller F; Imperiali M; Piccardo A; Giovanella L
    Clin Endocrinol (Oxf); 2020 Feb; 92(2):169-178. PubMed ID: 31742747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.
    Brancatella A; Viola N; Brogioni S; Montanelli L; Sardella C; Vitti P; Marcocci C; Lupi I; Latrofa F
    Eur Thyroid J; 2019 Jul; 8(4):192-195. PubMed ID: 31602361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graves' disease coexisted with resistance to thyroid hormone: a case report.
    Akahori H; Usuda R
    J Med Case Rep; 2021 Sep; 15(1):473. PubMed ID: 34560890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
    Kidokoro-Kunii Y; Emoto N; Cho K; Oikawa S
    J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
    Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report.
    Kurihara S; Oikawa Y; Nakajima R; Satomura A; Tanaka R; Kagamu H; Shimada A
    J Diabetes Investig; 2020 Jul; 11(4):1006-1009. PubMed ID: 31926048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of primary hyperthyroidism caused by Graves' disease admixed with resistance to thyroid hormone (P453T).
    Sato H
    Endocr J; 2010; 57(8):687-92. PubMed ID: 20574139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetrical Graves' disease in children: potential usefulness of potassium iodide monotherapy.
    Fukahori K; Sawano K; Yoshida H; Nagasaki K
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35459658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of post-partum Graves' thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy.
    Hidaka Y; Tamaki H; Iwatani Y; Tada H; Mitsuda N; Amino N
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):15-20. PubMed ID: 7914152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutoff value of thyroid uptake of (99m)Tc-pertechnetate to discriminate between Graves' disease and painless thyroiditis: a single center retrospective study.
    Uchida T; Suzuki R; Kasai T; Onose H; Komiya K; Goto H; Takeno K; Ishii S; Sato J; Honda A; Kawano Y; Himuro M; Yamada E; Yamada T; Watada H
    Endocr J; 2016; 63(2):143-9. PubMed ID: 26581846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
    Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N
    Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.